Adherex Technologies (FENC) Competitors

$10.70 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$10.54 -0.16 (-1.54%)

As of 07/2/2026 05:39 PM Eastern

FENC vs. KALV, INBX, DMRA, IMTX, and AVLN

Should you buy Adherex Technologies stock or one of its competitors? MarketBeat compares Adherex Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adherex Technologies include KalVista Pharmaceuticals (KALV), Inhibrx Biosciences (INBX), Damora Therapeutics, Inc. Common Stock (DMRA), Immatics (IMTX), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does Adherex Technologies compare to KalVista Pharmaceuticals?

Adherex Technologies (NASDAQ:FENC) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

55.5% of Adherex Technologies shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Adherex Technologies has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Adherex Technologies has higher revenue and earnings than KalVista Pharmaceuticals. Adherex Technologies is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$51.00M	7.32	-$9.74M	-$0.29	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

In the previous week, Adherex Technologies' average media sentiment score of 0.00 equaled KalVista Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Adherex Technologies	Neutral
KalVista Pharmaceuticals	Neutral

KalVista Pharmaceuticals has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Adherex Technologies currently has a consensus target price of $15.40, indicating a potential upside of 43.93%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 13.33%. Given Adherex Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Adherex Technologies is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Adherex Technologies beats KalVista Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Adherex Technologies compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Inhibrx Biosciences currently has a consensus target price of $150.00, indicating a potential upside of 53.72%. Adherex Technologies has a consensus target price of $15.40, indicating a potential upside of 43.93%. Given Inhibrx Biosciences' higher probable upside, research analysts plainly believe Inhibrx Biosciences is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Inhibrx Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Inhibrx Biosciences' average media sentiment score of 0.00 equaled Adherex Technologies'average media sentiment score.

Company	Overall Sentiment
Inhibrx Biosciences	Neutral
Adherex Technologies	Neutral

Adherex Technologies has higher revenue and earnings than Inhibrx Biosciences. Adherex Technologies is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,101.15	-$140.05M	-$8.39	N/A
Adherex Technologies	$51.00M	7.32	-$9.74M	-$0.29	N/A

Inhibrx Biosciences has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Summary

Inhibrx Biosciences and Adherex Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Adherex Technologies compare to Damora Therapeutics, Inc. Common Stock?

Adherex Technologies (NASDAQ:FENC) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Adherex Technologies has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than Adherex Technologies. MarketBeat recorded 1 mentions for Damora Therapeutics, Inc. Common Stock and 0 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.00 equaled Damora Therapeutics, Inc. Common Stock'saverage media sentiment score.

Company	Overall Sentiment
Adherex Technologies	Neutral
Damora Therapeutics, Inc. Common Stock	Neutral

Adherex Technologies presently has a consensus price target of $15.40, suggesting a potential upside of 43.93%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.43, suggesting a potential upside of 41.52%. Given Adherex Technologies' higher probable upside, research analysts clearly believe Adherex Technologies is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Adherex Technologies has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Adherex Technologies is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$51.00M	7.32	-$9.74M	-$0.29	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Summary

Adherex Technologies beats Damora Therapeutics, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Adherex Technologies compare to Immatics?

Adherex Technologies (NASDAQ:FENC) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Adherex Technologies has a net margin of -17.12% compared to Immatics' net margin of -572.35%. Adherex Technologies' return on equity of -43.87% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Immatics	-572.35%	-47.36%	-39.35%

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adherex Technologies has higher earnings, but lower revenue than Immatics. Adherex Technologies is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$51.00M	7.32	-$9.74M	-$0.29	N/A
Immatics	$54.60M	24.43	-$222.26M	-$1.99	N/A

Adherex Technologies has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Adherex Technologies presently has a consensus target price of $15.40, suggesting a potential upside of 43.93%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 109.05%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Immatics had 1 more articles in the media than Adherex Technologies. MarketBeat recorded 1 mentions for Immatics and 0 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.00 equaled Immatics'average media sentiment score.

Company	Overall Sentiment
Adherex Technologies	Neutral
Immatics	Neutral

Summary

Adherex Technologies and Immatics tied by winning 8 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Avalyn Pharma?

Adherex Technologies (NASDAQ:FENC) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Avalyn Pharma has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Avalyn Pharma's return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Avalyn Pharma	N/A	N/A	N/A

Avalyn Pharma has lower revenue, but higher earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$51.00M	7.32	-$9.74M	-$0.29	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

In the previous week, Adherex Technologies' average media sentiment score of 0.00 equaled Avalyn Pharma'saverage media sentiment score.

Company	Overall Sentiment
Adherex Technologies	Neutral
Avalyn Pharma	Neutral

Adherex Technologies presently has a consensus target price of $15.40, indicating a potential upside of 43.93%. Avalyn Pharma has a consensus target price of $59.00, indicating a potential upside of 98.45%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Avalyn Pharma is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

55.5% of Adherex Technologies shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Avalyn Pharma beats Adherex Technologies on 7 of the 12 factors compared between the two stocks.

Get Adherex Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FENC vs. The Competition

Export

Metric	Adherex Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$373.29M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-36.90	21.61	28.02	24.70
Price / Sales	7.32	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	10.29	8.66	10.96	6.46
Net Income	-$9.74M	$23.81M	$3.57B	$337.01M
7 Day Performance	-2.90%	3.39%	2.12%	1.69%
1 Month Performance	22.99%	10.81%	5.25%	3.81%
1 Year Performance	23.20%	62.61%	33.29%	23.90%

Adherex Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FENC Adherex Technologies	4.2073 of 5 stars	$10.70 flat	$15.40 +43.9%	+23.2%	$373.29M	$51.00M	N/A	10	Positive News
KALV KalVista Pharmaceuticals	2.2534 of 5 stars	$27.00 flat	$30.60 +13.3%	N/A	$1.44B	$1.43M	N/A	100
INBX Inhibrx Biosciences	2.2128 of 5 stars	$95.31 +0.2%	$150.00 +57.4%	+499.2%	$1.40B	$1.30M	N/A	166
DMRA Damora Therapeutics, Inc. Common Stock	3.0016 of 5 stars	$22.57 +2.6%	$42.43 +88.0%	+769.0%	$1.35B	N/A	N/A	40	Gap Down
IMTX Immatics	1.933 of 5 stars	$9.52 -5.0%	$20.80 +118.5%	+76.4%	$1.34B	$54.60M	N/A	260	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FENC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adherex Technologies (FENC) Competitors

FENC vs. KALV, INBX, DMRA, IMTX, and AVLN

How does Adherex Technologies compare to KalVista Pharmaceuticals?

Summary

How does Adherex Technologies compare to Inhibrx Biosciences?

Summary

How does Adherex Technologies compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Adherex Technologies compare to Immatics?

Summary

How does Adherex Technologies compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adherex Technologies (FENC) Competitors

FENC vs. KALV, INBX, DMRA, IMTX, and AVLN

How does Adherex Technologies compare to KalVista Pharmaceuticals?

Do insiders and institutionals believe in FENC or KALV?

Which has more risk & volatility, FENC or KALV?

Which has higher valuation & earnings, FENC or KALV?

Does the media refer more to FENC or KALV?

Is FENC or KALV more profitable?

Do analysts rate FENC or KALV?

Summary

How does Adherex Technologies compare to Inhibrx Biosciences?

Do analysts recommend INBX or FENC?

Which has more risk and volatility, INBX or FENC?

Do insiders & institutionals believe in INBX or FENC?

Does the media prefer INBX or FENC?

Which has higher earnings and valuation, INBX or FENC?

Is INBX or FENC more profitable?

Summary

How does Adherex Technologies compare to Damora Therapeutics, Inc. Common Stock?

Which has more risk and volatility, FENC or DMRA?

Does the media refer more to FENC or DMRA?

Do analysts rate FENC or DMRA?

Do institutionals & insiders hold more shares of FENC or DMRA?

Is FENC or DMRA more profitable?

Which has stronger earnings & valuation, FENC or DMRA?

Summary

How does Adherex Technologies compare to Immatics?

Is FENC or IMTX more profitable?

Do institutionals & insiders hold more shares of FENC or IMTX?

Which has better valuation and earnings, FENC or IMTX?

Which has more volatility and risk, FENC or IMTX?

Do analysts prefer FENC or IMTX?

Does the media refer more to FENC or IMTX?

Summary

How does Adherex Technologies compare to Avalyn Pharma?

Is FENC or AVLN more profitable?

Which has better valuation and earnings, FENC or AVLN?

Does the media prefer FENC or AVLN?

Do analysts rate FENC or AVLN?

Do insiders & institutionals believe in FENC or AVLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools